FindTrial
Sign In

Lenvatinib + PD-1 monoclonal antibody

DRUG3 trials

Sponsors

Xu Yong, MD, First Hospital of China Medical University

Conditions

BCLC Stage B Hepatocellular CarcinomaBCLC Stage C Hepatocellular CarcinomaHCC - Hepatocellular CarcinomaHepatic Arterial Infusion ChemotherapyLenvatinibLiver CancerPD-1PD-1 Inhibitors

Phase 2

Gut Microbiota in Liver Cancer (Treated With TKIs In Combination With ICIs)
Not yet recruitingNCT06563934
Xu Yong, MDLiver Cancer
Start: 2024-08-30End: 2026-11-20Target: 70Updated: 2024-08-21

Unknown Phase

HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC
RecruitingNCT06632093
First Hospital of China Medical UniversityBCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy +3
Start: 2024-09-16End: 2025-12-30Target: 84Updated: 2024-10-08
HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)
CompletedNCT06631326
First Hospital of China Medical UniversityHCC - Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy, BCLC Stage C Hepatocellular Carcinoma +2
Start: 2021-01-01End: 2025-10-22Updated: 2026-01-27

Related Papers

Hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitors as first-line treatment for hepatocellular carcinoma with high tumor burden and portal vein tumor thrombus: A target trial emulation study (CHANCE 2416).
Journal of Clinical Oncology2026-05-27
Hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitors versus lenvatinib plus PD-1 inhibitors as first-line treatment for hepatocellular carcinoma with high tumour burden and portal vein tumour thrombus (CHANCE 2416): study protocol of a multicentre, retrospective, target trial emulation design
BMJ Open2025-09-01
Hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitors as first-line treatment for hepatocellular carcinoma with high tumor burden and portal vein tumor thrombus.
Journal of Clinical Oncology2025-05-28